NCT05269121: A trial that was reported late by Adaptive Phage Therapeutics, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05269121 |
|---|---|
| Title | An Open-Label Multicenter Study to Evaluate the Safety and Efficacy of PhageBank⢠Phage Therapy in Conjunction With Debridement, Antibiotics, and Implant Retention (DAIR) for Patients With First Time Culture Proven Chronic Prosthetic Joint Infection |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 31, 2022 |
| Completion date | Nov. 30, 2023 |
| Required reporting date | Nov. 29, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 23, 2024 |
| Days late | None |